Incidence of and Risk Factors for Fibrosing Colonopathy in Patients With Cystic Fibrosis
Full IRB Study Title:
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors
IRB Study ID: 996785-2
For complete information, please view the study on clinicaltrials.gov
Lead Investigator
Gregory Omlor, MD, FAAP
Director, Lewis H Walker CF Center; Pediatric Pulmonologist; Pediatric Sleep Medicine
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Medicine